Complete response in anaplastic lymphoma kinase–rearranged oncocytic thyroid cancer: A case report and review of literature
Victoire de Salins, Gokoulakrichenane Loganadane, Charlotte Joly, Mukedaisi Abulizi, Maya Nourieh, H. Boussion, Yazid Belkacémi, Christophe Tournigand, Emmanuelle Kempf
Abstract
BACKGROUND: rearrangements in thyroid tumor is a promising therapeutic track, and treatments need to be explored. CASE SUMMARY: inhibitor. A positron emission tomography scan performed 4 mo after the initiation of crizotinib showed a complete metabolic response. CONCLUSION: -rearranged thyroid tumor, and the need of further assessments.
Topics & Concepts
CrizotinibMedicineAnaplastic lymphoma kinaseThyroid cancerThyroidGene rearrangementPathologyAnaplastic carcinomaCancer researchLung cancerInternal medicineOncologyBiochemistryChemistryGeneMalignant pleural effusionThyroid Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsGenetic factors in colorectal cancer